Raymond James Got Ra Pharmaceuticals (RARX) Covered with $18 Target.

June 29, 2018 - By Kevin Carney

What Price Target Has Raymond James Given Ra Pharmaceuticals (RARX)

On Thursday, 28 June an analyst report was revealed to clients and investors on Ra Pharmaceuticals (RARX) of its Outperform Rating kept by stock analysts at Raymond James. The market cap company coverage initiated with $18 price target that would suggest 79.82 % upside potential from the previous stock close.

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Ratings Coverage

A total of 3 analysts rate Ra Pharmaceuticals (RARX) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (RARX) has 4 ratings reports on Jun 29, 2018 according to StockzIntelligence. In Thursday, March 15 report BMO Capital Markets maintained the stock with “Outperform” rating. On Thursday, January 18 the firm earned “Buy” rating by Credit Suisse. In Tuesday, February 13 report Credit Suisse maintained it with “Outperform” rating and $14 target.

The stock increased 1.11% or $0.1103 during the last trading session, hitting $10.0103.Ra Pharmaceuticals, Inc. has volume of 80,986 shares. Since June 29, 2017 RARX has declined 75.06% and is downtrending. RARX underperformed by 87.63% the S&P 500.

Ra Pharmaceuticals, Inc. (NASDAQ:RARX)’s earnings release is awaited by WallStreet on August, 8, according to Faxor. Last year’s EPS was $-0.56, while now analysts expect change of 5.36 % up from current $-0.53 EPS. Wall Street predicts -13.11 % EPS growth as of August, 8.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States.The firm is valued at $323.20 million. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.Last it reported negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria ; and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN).

A couple more Ra Pharmaceuticals, Inc. (NASDAQ:RARX) news were posted by: Businesswire.com which released on May 31, 2018 “Ra Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference”, also Businesswire.com on June 05, 2018 posted “Congress of the European Academy of Neurology”, the next Benzinga.com is “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018. Businesswire.com has article titled “Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC …”.

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: